

Vermont Oxford Network
Revisions for Manual of Operations, Part 2, Version 16.2
February 1, 2012

Correction to Item 31: Treatment of ROP with Anti-VEGF Drug

The definition has been modified to correct a misprint. The definition on page 24 now reads:

Answer "**Yes**" if the infant received bevacizumab (Avastin) or other **anti**-vascular endothelial growth factor (anti-VEGF) drug in one or both eyes for the treatment of retinopathy of prematurity (ROP).

Answer "**No**" if the infant did not receive bevacizumab (Avastin) or other anti-VEGF in one or both eyes for the treatment of retinopathy of prematurity (ROP).

Correction to Item 40b: NEC, Where Occurred

The following note was mistakenly omitted and has been added back to the definition on page 32:

Note: Recurrence or recrudescence of NEC that had previously occurred at another hospital will not be considered to be NEC that occurred at your hospital unless the original case of NEC had resolved and the infant had been on full feedings for 1 week or more.